Mustang Bio, Inc. MBIO
Mustang Bio, Inc. (Nasdaq: MBIO) is an oncology drug developer. Its lead program, MB-101 (IL13Ra2-targeted CAR T) / MB-109 (MB-101 + MB-108 oncolytic HSV-1), is in Phase 1 for IL13Ra2+ recurrent glioblastoma and high-grade astrocytoma. Its next catalyst on record is MB-109: Potential initiation of investigator-sponsored single-institution Phase 1 trial at City of Hope (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: MB-109 — Potential initiation of investigator-sponsored single-institution Phase 1 trial at City of Hope (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| MB-109 (MB-101 CAR T + MB-108 oncolytic virus) | Recurrent GBM / high-grade astrocytoma | cell therapy | Phase 1 |
| MB-101 (IL13Ra2 CAR T) | Recurrent malignant glioma | cell therapy | Phase 1 |
| MB-108 (C134 HSV-1 oncolytic virus) | Malignant glioma / GBM | biologic-other | Phase 1 |
Recent results and decisions
- Oct 13, 2026n/a Nasdaq grants additional 180-day grace period until April 12, 2027 to regain compliance with minimum bid price requirement.
On October 13, 2026, the Company received a letter from the Staff granting the Company's request for an additional 180-calendar day period, or until April 12, 2027, to regain compliance with the Bid Price Requirement.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.